WeChat mobile mini-application
OtherSexual health education and the role of PrEP
NCT Number: NCT04754139
This study aims to use a social media mini-application-enabled intervention to successfully promote the initiation and persistence of pre-exposure prophylaxis (PrEP) among at-risk people 18 years and above (including men who have sex with men (MSM), transgender women, sex workers, and other key populations) in Wuhan and Guangzhou, China.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Guangzhou Eighth People's Hospital, Guangzhou, China
The China National Medical Products Administration (NMPA) recently approved TDF/FTC (Truvada) for PrEP making it the first HIV prevention medicine available in China. While this is a significant step in addressing the country's rising rates of new HIV diagnoses, implementation and scale-up of this resource will be the next challenge.
3200 at-risk adults will be engaged by word of mouth and social media. Individuals will be asked to complete a survey of risk and PrEP interest, to download the study mobile mini-application onto their cell phone, and will be offered an HIV and syphilis screen. One thousand two hundred of these subjects who are eligible and willing to start PrEP will be enrolled in the study. The first 700 participants enrolled in each site will complete an additional four-phased, WeChat-based adherence intervention through a stepped-wedge design, with each cluster starting at three-month intervals.
Enrolled participants will undergo baseline laboratory testing before brought to a collaborating hospital where an established physician will provide TDF/FTC and arrange follow-up. Rural and out-of-town enrollees may undergo testing at an outside lab. All subjects will be encouraged to keep using the mini-application for receiving constant health education and counseling support on HIV/STI prevention, PrEP initiation and/or adherence management. Subjects on PrEP will be contacted every three months over the course of two years to answer questions on adherence including number of missed pills and/or sex events not covered by on-demand PrEP, adverse effect, and utilization of the mini-application. 120 enrollees in Guangdong will additionally participate in a pill count adherence sub study that counts the number of unused pills at each clinical follow-up
A PrEP messaging open contest will be organized to assess the best images and videos to enhance PrEP adherence among those who start PrEP. New content will be developed using crowdsourcing and introduced into the mini-application at staggered times. The effect of this content will be evaluated through a stepped wedge approach nested within this single arm study.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Sexual health education and the role of PrEP
Time frame: 2 years
Number of PrEP prescriptions fulfilled in Wuhan and Guangzhou, China
Time frame: 2 years
Number of HIV screenings performed
Time frame: 2 years
Number of syphilis screenings performed
Time frame: 12 months
Number of subjects retained in PrEP care at 6 and 12 months
Time frame: 2 years
Number of subjects that self-report PrEP adherence
Time frame: 2 years
Number of new HIV infections reported in PrEP users
Time frame: 2 years
Number of new syphilis infections reported in PrEP users
University of Chicago
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06566417
HIV Preexposure Prophylaxis, HIV Prevention
Kisumu, Kenya
View Trial DetailsNCT04424524
HIV Preexposure Prophylaxis, HIV Prevention
Thika, Kenya
View Trial DetailsNCT02074891
HIV Chemoprophylaxis, HIV Preexposure Prophylaxis
Washington D.C., District of Columbia, United States
View Trial DetailsNCT03893188
HIV Preexposure Prophylaxis
Aarau, Canton of Aargau, Switzerland
View Trial Details